Fertility and Social Reintegration After Modified CODOX-M/IVAC With or Without Rituximab: A Questionnaire Survey of Non-Hodgkin Lymphoma

Hematological Oncology - United Kingdom
doi 10.1002/hon.2439_109
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Excellent Real-World Outcomes of Adults With Burkitt Lymphoma Treated With CODOX-M/IVAC Plus or Minus Rituximab

British Journal of Haematology
Hematology
2018English

Subcutaneous Rituximab in B-Cell Non-Hodgkin Lymphoma: A Single-Center Experience

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Maintenance Rituximab or Observation After Frontline Treatment With Bendamustine-Rituximab for Follicular Lymphoma

British Journal of Haematology
Hematology
2018English

Characteristics and Management of Rash Following Lenalidomide and Rituximab in Patients With Untreated Indolent Non-Hodgkin Lymphoma

Haematologica
Hematology
2015English

Regulation of CD20 in Rituximab-Resistant Cell Lines and B-Cell Non-Hodgkin Lymphoma

Clinical Cancer Research
Cancer ResearchOncology
2012English

Time and Motion Study for Rituximab Sc vs Iv in Colombian Patients With Non-Hodgkin Lymphoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Non-Hodgkin Lymphoma

2020English

Occurrence of Sarcoidosis After Chemotherapy for Non-Hodgkin Lymphoma

Korean Journal of Internal Medicine
Internal Medicine
2016English

High-Dose Methotrexate With or Without Rituximab in Newly Diagnosed Primary CNS Lymphoma

Neurology
Neurology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy